No quarterly revenue total was found in GRI BIO, INC.'s SEC filings.
Gri Bio, Inc. (GRI) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $10.9 million in cash and investments and $44,000 in total debt.
Revenue
—
Net income
$-1.64M
+43.2% vs year-ago quarter
Operating cash flow
$-1.45M
+54.3% vs year-ago quarter
Free cash flow
$-2.00M
+11.9% vs prior quarter
EPS
$-0.91
+97.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.19M
-13.1% vs year-ago quarter
Net cash
$10.90M
Q2 FY2026
Operating margin
9291.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GRI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1824293
- Former names
- Vallon Pharmaceuticals, Inc. (until Apr 21, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.6M | -$2.0M | -$2.7M | -$3.4M | -$2.9M |
| Net income | -$1.6M | -$2.0M | -$2.7M | -$3.4M | -$2.9M |
| Diluted EPS | -$0.91 | -$1.61 | $0.54 | -$1.28 | -$36.72 |
| Operating cash flow | -$1.4M | -$3.7M | -$3.0M | -$2.3M | -$3.2M |
| Total assets | $11.4M | $11.3M | $8.7M | $4.8M | $5.7M |
| Total liabilities | $1.1M | $794,000 | $2.7M | $2.8M | $2.4M |
| Stockholders' equity | $10.3M | $10.5M | $6.0M | $2.0M | $3.3M |
| Cash and investments | $10.9M | $11.0M | $8.2M | $4.1M | $5.1M |
| Total debt | $44,000 | $58,000 | $71,000 | $84,000 | $96,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Nov 4, 2026 | Nov 4, 2026 |
| ARS | Annual report to shareholders | Sep 28, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
May 14, 2026 | May 14, 2026 |
All 402 Gri Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.